Fertility Awareness Biomarkers

Pilot Evaluation of a New Urine Progesterone Test to Confirm Ovulation in Women Using a Fertility Monitor

Bouchard TP, Fehring RJ, Schneider M

Published July 2, 2019 Frontiers in public health, 7, 184
DOI 10.3389/fpubh.2019.00184 PMID 31312631 PMC PMC6614355

RRM Academy Synopsis

Low-threshold progesterone test confirmed ovulation in 14 of 17 cycles

A lower-threshold urine progesterone strip confirmed ovulation in about 8 out of 10 cycles, against about 6 out of 10 for a higher-threshold strip. In this pilot study, 13 Marquette Method users and teachers with a hormonal fertility monitor supplied 34 cycles of data.

Study at a glance, pilot study: A lower-threshold urine strip confirmed ovulation in 14 of 17 cycles
Study at a glance, pilot study of 13 Marquette Method users and teachers: A lower-threshold urine strip confirmed ovulation in 14 of 17 cycles. Source: Bouchard TP et al., 2019, PMID 31312631.

Key Findings

  • Across 34 menstrual cycles from 13 women (mean age 33.6), mean cycle length was 28.4 days and the luteal phase lasted 10 to 16 days.
  • Among 17 cycles tested with the lower-threshold strips, 14 (82.4%) had a positive PDG test; the 95% confidence interval was 0.64 to 1.00.
  • Among 17 cycles tested with the higher-threshold strips, 10 (59%) had a positive PDG test; the 95% confidence interval was 0.36 to 0.82.
  • Positive tests appeared 2 to 10 days after the monitor's second Peak LH reading, most frequently on days 4 and 5. Every lower-threshold positive fell 2 to 5 days after the surge.

Interpretation

This pilot study tracked 13 Marquette Method users and teachers over 34 cycles, measuring how often a home urine progesterone strip detected the hormone rise that follows the monitor's second Peak LH reading, the sign the authors used to confirm ovulation. Participants were women aged 26 to 46 with regular cycles. The authors judge the lower-threshold strip more appropriate for clinical use. The authors note that testing larger groups for 7 days or more would add to these findings. The findings support further study of the lower-threshold progesterone test as a home tool for confirming ovulation.

RRM Context

The Marquette Method, a fertility awareness-based method, charts hormone readings from a home monitor. A progesterone result on the same chart gives evidence that ovulation has occurred. That supports the restorative principle of observing the cycle.

Abstract

Background

Progesterone rises ~24-36 h after ovulation. Past studies using ultrasound-confirmed ovulation have shown that three consecutive tests with a threshold of 5μg/mL of urine progesterone (pregnanediol-3-glucuronide, PDG), taken after the luteinizing hormone (LH) surge, confirmed ovulation with 100% specificity.

Purpose

The purpose of this study was to a evaluate a new urine PDG self-test to retrospectively confirm ovulation in women who were monitoring ovulation using a hormonal fertility monitor.

Methods

Thirteen women of reproductive age were recruited to test urine PDG while using their home hormonal fertility monitor. The monitor measured the rise in estrogen (estrone-3-glucuronide, E3G) and LH to estimate the fertile phase of the menstrual cycle. The women used an online menstrual cycle charting system to track E3G, LH and PDG levels for four menstrual cycles.

Results

The participants (Mean age 33.6) produced 34 menstrual cycles of data (Mean length 28.4 days), 17 of which used a PDG test with a threshold of 7μg/mL and 17 with a threshold of 5μg/mL. In the cycles that used the 7μg/mL test strips, 59% had a positive confirmation of ovulation, and with the 5μg/mL test strips, 82% of them had a positive confirmation of ovulation.

Conclusion

The 5μg/mL PDG test confirmed ovulation in 82% of cycles and could assist women in the evaluation of the luteal progesterone rise of their menstrual cycle.

Topics

By this author

Related research

Fertility Awareness › Biomarkers › Urinary Hormone Monitoring · Reproductive Endocrinology › Ovulation Physiology › Anovulation · Menstrual Cycle › Cycle Biomarkers › Hormonal Markers
Thomas P Bouchard, Richard J Fehring, Mary Schneider
Tom Bouchard, T Bouchard, Rick Fehring, Dick Fehring, Rich Fehring, R Fehring, M Schneider
PMID 31312631 31312631 DOI 10.3389/fpubh.2019.00184 10.3389/fpubh.2019.00184 Bouchard et al. 2019, Bouchard 2019